Welcome to our dedicated page for UpStream Bio news (Ticker: UPB), a resource for investors and traders seeking the latest updates and insights on UpStream Bio stock.
Upstream Bio, Inc. (NASDAQ: UPB) is a clinical-stage biotechnology company developing verekitug, a monoclonal antibody antagonist of the thymic stromal lymphopoietin (TSLP) receptor, for severe respiratory inflammatory diseases. The UPB news feed on Stock Titan highlights company announcements that explain how this single asset is progressing through clinical development and what that may mean for chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD).
Investors following UPB can find press releases on positive top-line data from the VIBRANT Phase 2 trial in CRSwNP, where verekitug dosed every 12 weeks met its primary endpoint and key secondary endpoints with a generally well tolerated safety profile. News items also cover structural and mechanistic data presented at scientific congresses, detailing how verekitug binds the TSLP receptor, prevents TSLP binding, and outcompetes TSLP even in the presence of preformed receptor complexes.
Additional updates include reports on enrollment and design of the VALIANT Phase 2 trial in severe asthma, the VENTURE Phase 2 trial in COPD, and the VALOUR long-term extension study. Financial results releases, furnished via Form 8-K, summarize research and development spending related to verekitug and provide context on the company’s cash position and operating expenses.
News coverage also tracks Upstream Bio’s participation in healthcare and biopharma investor conferences, where management discusses clinical progress and upcoming milestones. For anyone monitoring UPB stock or the development of TSLP receptor-targeted therapies in respiratory disease, this page aggregates the company’s official news and regulatory communications in one place.
Upstream Bio (NASDAQ:UPB) announced positive top-line results from its Phase 2 VIBRANT trial evaluating verekitug for treating chronic rhinosinusitis with nasal polyps (CRSwNP). The trial met its primary endpoint with verekitug, dosed every 12 weeks, achieving a significant placebo-adjusted reduction in nasal polyp score of -1.8 (p<0.0001).
The study demonstrated significant improvements in key secondary endpoints, including a -0.8 reduction in nasal congestion score (p=0.0003) and 76% reduction (p=0.03) in need for surgery or systemic corticosteroids. The drug showed a favorable safety profile with no serious adverse events reported. Notably, verekitug's clinical effect appears to meet or exceed that of other biologics in CRSwNP at 24 weeks.
Upstream Bio (NASDAQ:UPB) has scheduled a conference call and webcast for September 2, 2025, at 8:00 a.m. ET to present top-line data from its Phase 2 VIBRANT trial. The study evaluates verekitug, a unique monoclonal antibody targeting TSLP receptor, in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
The VIBRANT trial (NCT06164704) is a global, randomized, placebo-controlled study where participants received either 100 mg of verekitug or placebo subcutaneously every 12 weeks for 24 weeks. The trial's primary endpoint focuses on measuring changes in endoscopic nasal polyp score at Week 24.
Upstream Bio (NASDAQ:UPB) reported Q2 2025 financial results and clinical progress for its lead drug verekitug, the only monoclonal antibody targeting TSLP receptor in development. The company highlighted three key clinical trials: VIBRANT (CRSwNP) with top-line data expected in Q3 2025, VALIANT (severe asthma) with results in Q1 2026, and VENTURE (COPD) which dosed its first patient in July 2025.
Financially, Upstream reported cash position of $393.6 million, expected to fund operations through 2027. Q2 2025 showed a net loss of $40.0 million, up from $14.7 million in Q2 2024, primarily due to increased R&D expenses of $37.9 million and G&A expenses of $7.4 million.
[ "Strong cash position of $393.6 million, funding operations through 2027", "Completed enrollment in Phase 2 severe asthma trial ahead of Q1 2026 data readout", "On track for CRSwNP Phase 2 trial results in Q3 2025", "Expanded clinical program with first COPD patient dosed in July 2025" ]Upstream Bio (NASDAQ:UPB) has initiated dosing in its Phase 2 clinical trial, VENTURE, evaluating verekitug for Chronic Obstructive Pulmonary Disease (COPD). The trial will assess approximately 670 adults with moderate-to-severe COPD, testing doses of 100 mg every 12 weeks or 400 mg every 24 weeks versus placebo.
This expansion marks verekitug's third indication in development, alongside ongoing Phase 2 trials in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma. The company has completed enrollment for both existing trials, with data expected in Q3 2025 for CRSwNP and Q1 2026 for severe asthma.
Verekitug, as the only known biologic targeting the TSLP receptor, aims to improve COPD treatment through less frequent dosing and potentially differentiated efficacy compared to existing biologics.
Upstream Bio (Nasdaq: UPB) has appointed Stacy Price as Chief Technology Officer. Price brings over 25 years of experience in technical operations, manufacturing, and product development in biotechnology. In her new role, she will oversee technical operations and product development expansion for verekitug, focusing on CMC processes and drug delivery.
Price previously served as Chief Technology and Manufacturing Officer at Invivyd and Chief Technical Officer at Akouos. She also held senior leadership positions at Ziopharm Oncology, Shire, and Transkaryotic Therapies. Price holds an M.S. in Biochemical Engineering and a B.S. in Chemical Engineering from Tufts University.
Upstream Bio (Nasdaq: UPB) has reported its Q4 and full year 2024 financial results, highlighting significant progress in its clinical programs. The company completed enrollment for its Phase 2 trial of verekitug in chronic rhinosinusitis with nasal polyps (CRSwNP), with top-line data expected in H2 2025.
Financial highlights include a successful upsized IPO raising $293 million in gross proceeds, with cash reserves of $470.5 million as of December 31, 2024, extending runway through 2027. Q4 2024 showed R&D expenses of $21.8 million (up from $11.6 million in Q4 2023) and G&A expenses of $5.2 million (up from $3.2 million in Q4 2023). Net loss increased to $21.2 million compared to $11.8 million in Q4 2023.
The company is advancing verekitug development in multiple respiratory diseases, including severe asthma (Phase 2 data expected H2 2026) and COPD (first patient dosing expected H2 2025).